Stockscreener 앱 받기
3.15
1.56%
-0.05
시간 외 거래:
3.15
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Will Galectin Therapeutics Inc. stock continue dividend increasesJuly 2025 Closing Moves & Detailed Earnings Play Strategies - ulpravda.ru
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Last Week's 23% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Can Galectin Therapeutics Inc. (PHPN) stock sustain institutional flowsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - ulpravda.ru
Is Galectin Therapeutics Inc. (PHPN) stock a safe buy pre earningsJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Galectin Therapeutics Inc. stock benefit from automationJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - ulpravda.ru
Fraud Investigation Opened: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - ulpravda.ru
How buybacks impact Galectin Therapeutics Inc. stock value2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - Chartmill
Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Galectin Therapeutics CFO sells $233k in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics CFO sells $233k in shares - Investing.com
Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin The - GuruFocus
Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CEO Sells 18,571 Shares of Stock - MarketBeat
Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock - MarketBeat
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9% - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin ... - Bluefield Daily Telegraph
Should I hold or sell Galectin Therapeutics Inc. stock in 20252026 world cup usa national team qualification top scorers build up play knockout prediction preview - ulpravda.ru
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics reveals promising NAVIGATE trial results - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Inflation Data: Why Galectin Therapeutics Inc stock could rally in 2025Market Movers & Reliable Breakout Forecasts - moha.gov.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors ofGALT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Investors to Reach Out - ACCESS Newswire
Galectin Therapeutics Shares Plunge 28.9% Following FDA Response on Belapectin Development - Intellectia AI
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm - The AI Journal
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares - Investing.com Australia
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock By Investing.com - Investing.com Nigeria
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares By Investing.com - Investing.com South Africa
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares By Investing.com - Investing.com South Africa
Galectin therapeutics director Kevin Freeman buys $19,514 in stock By Investing.com - Investing.com Canada
Galectin therapeutics director Kevin Freeman buys $19,514 in stock - Investing.com
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares - Investing.com
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 By Investing.com - Investing.com Nigeria
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock - Investing.com
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 - Investing.com India
0.90%
자본화:
|
볼륨(24시간):